Glenmark launches new diabetes drug in India

6 October 2022

Glenmark Pharmaceuticals’ (BSE: 532296) shares rose 1.2% to 408.75 rupees today, after the Indian drugmaker announced that it became the first company in India to launch thiazolidinedione lobeglitazone for the treatment of type 2 diabetes in adults.

Marketed under the brand name LOBG; it contains lobeglitazone (0.5mg) and to be taken once daily under prescription to improve glycemic control in adult diabetic patients. Indians have a high prevalence of insulin resistance and that makes LOBG an appealing treatment option in managing uncontrolled type 2 diabetes among insulin‐resistant diabetic patients.

Glenmark earlier received approval from the Indian drug regulator, Drug Controller General of India, for manufacturing and marketing lobeglitazone based on a randomized, double‐blind Phase III clinical trial conducted on adult type 2 diabetic patients, aged 18 years and older. The results of this trial have shown a faster and improved glycemic control with lobeglitazone.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK